Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Epcoritamab + rituximab + lenalidomide versus rituximab + lenalidomide in relapsed or refractory follicular lymphoma
NL-OMON59620Phase 3Active, not recruiting
- Sponsor
- AbbVie Inc.
- Start
- Mar 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised trial in follicular lymphoma (FL) comparing Epcoritamab + rituximab + lenalidomide with Rituximab + lenalidomide (2 arms). Primary endpoints: Progression-free survival and Best overall response. Started Mar 2023; status: active, not recruiting.
02
Drugs
epcoritamabrituximablenalidomide
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on NL-OMON59620.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59620.